Join Amazon Prime and ship Two-Day for free and Overnight for $3.99. Already a member? Sign in.
|
|||||||||
Better Together
Customers Who Bought This Item Also Bought
The Truth About the Drug Companies: How They Deceive Us and What to Do About It by Marcia Angell  (86)
$10.85
|
Science at the Bar: Science and Technology in American Law (Twentieth Century Fund Books/Reports/Studies) by Sheila Jasanoff  (3)
$27.00
|
The Structure of Scientific Revolutions by Thomas S. Kuhn (116)
$10.40
|
Silicone Spills: Breast Implants on Trial by Mary White Stewart  (4)
$38.95
|
End-of-Life Decision Making: A Cross-National Study (Basic Bioethics) by Robert H. Blank
$16.00
|
Editorial Reviews
Amazon.com
Introduced in 1962, silicone breast implants had been used by between one and two million women by the time they were virtually banned in 1992 by David A. Kessler of the Food and Drug Administration. While the ban came about because manufacturers had failed to demonstrate the safety of the devices, Marcia Angell, executive editor of The New England Journal of Medicine, argues that there actually was no medical consensus to support the contention that implants could cause widespread illness. Science on Trial examines the silicone debate and argues for the reliance on scientific evidence "to curb the greed, fear and self-indulgence" of such disputes. --This text refers to an out of print or unavailable edition of this title.
From Publishers Weekly
Angell, executive editor of the New England Journal of Medicine, explores here a preposterous situation: an industrial giant, Dow Corning, forced into Chapter 11 bankruptcy by numerous lawsuits filed on behalf of recipients of Dow's silicone breast implants?despite the fact that medical evidence to date shows no link between implants and autoimmune disorders, cancer or any other disease. In a style that ranges from gently didactic to plodding, Angell describes the events leading up to the FDA's ban on implants, the torrent of lawsuits that followed and the implications of the verdicts?overwhelmingly favorable to the plaintiffs and often carrying cash awards in the millions of dollars?for science and industry. Manufacturers have threatened to stop producing heart valves, shunts and other vital medical devices because of the threat of liability; further, suppliers of raw materials for these devices often refuse to sell to American companies for fear of ending up in an American courtroom. The author gives a clear explanation of the way science calculates risk (by considering populations, not individuals) and ably contrasts this with our judicial system, where the focus is on the individual seeking restitution. Angell is an effective champion of the scientific method and does a good job of exposing the chaos caused by a runaway tort system, but she offers no resolution to the state of affairs she describes.
Copyright 1996 Reed Business Information, Inc. --This text refers to an out of print or unavailable edition of this title.
See all Editorial Reviews
Introduced in 1962, silicone breast implants had been used by between one and two million women by the time they were virtually banned in 1992 by David A. Kessler of the Food and Drug Administration. While the ban came about because manufacturers had failed to demonstrate the safety of the devices, Marcia Angell, executive editor of The New England Journal of Medicine, argues that there actually was no medical consensus to support the contention that implants could cause widespread illness. Science on Trial examines the silicone debate and argues for the reliance on scientific evidence "to curb the greed, fear and self-indulgence" of such disputes. --This text refers to an out of print or unavailable edition of this title.
From Publishers Weekly
Angell, executive editor of the New England Journal of Medicine, explores here a preposterous situation: an industrial giant, Dow Corning, forced into Chapter 11 bankruptcy by numerous lawsuits filed on behalf of recipients of Dow's silicone breast implants?despite the fact that medical evidence to date shows no link between implants and autoimmune disorders, cancer or any other disease. In a style that ranges from gently didactic to plodding, Angell describes the events leading up to the FDA's ban on implants, the torrent of lawsuits that followed and the implications of the verdicts?overwhelmingly favorable to the plaintiffs and often carrying cash awards in the millions of dollars?for science and industry. Manufacturers have threatened to stop producing heart valves, shunts and other vital medical devices because of the threat of liability; further, suppliers of raw materials for these devices often refuse to sell to American companies for fear of ending up in an American courtroom. The author gives a clear explanation of the way science calculates risk (by considering populations, not individuals) and ably contrasts this with our judicial system, where the focus is on the individual seeking restitution. Angell is an effective champion of the scientific method and does a good job of exposing the chaos caused by a runaway tort system, but she offers no resolution to the state of affairs she describes.
Copyright 1996 Reed Business Information, Inc. --This text refers to an out of print or unavailable edition of this title.
See all Editorial Reviews
Product Details
|
